nach oben

World Journal of Urology

Erschienen in:

06.03.2018 | Original Article

Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review

verfasst von: Jianzhong Zhang, Bin Yang, Wenhui Xiao, Xiao Li, Hongjun Li

Erschienen in: World Journal of Urology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Testosterone supplement treatment (TST) is a classic therapy for hypogonadal men with type 2 diabetes mellitus (T2DM), but the effects of TST in different studies are inconsistent. We conducted this meta-analysis to evaluate the precise role of TST in hypogonadal men with T2DM.

Methods

PubMed, Embase, Cochrane Library and Web of Science were searched to identify qualified randomized controlled trials (RCTs). Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated to measure the specific effects of TST. Trial sequential analysis was performed to verify the pooled results.

Results

A total of eight RCTs were enrolled in our meta-analysis, including 596 hypogonadal participants with T2DM. Compared with comparators, TST can significantly improve glycemic control by reducing homeostatic model assessment of insulin resistance (MD − 0.79, 95% CI − 1.23 to − 0.34), fasting glucose (MD − 0.98, 95% CI − 1.13 to − 0.54), fasting insulin (MD − 2.47, 95% CI − 3.99 to − 0.95) and HbA1c% (MD − 0.45, 95% CI − 0.73 to − 0.16). In addition, TST can result in a decline in cholesterol (MD − 0.29, 95% CI − 0.38 to − 0.19) and triglyceride (MD − 0.37, 95% CI − 0.59 to − 0.15).

Conclusion

Our results indicated that TST can improve glycemic control and decrease TC and TG in hypogonadal patients with T2DM. We recommend TST during the anti-diabetic therapy in these patients.

Nur mit Berechtigung zugänglich

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559. https://doi.org/10.1210/jc.2009-2354 CrossRefPubMed

Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 30:1–9. https://doi.org/10.2164/jandrol.108.006486 CrossRefPubMed

Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE, McKinlay JB (2008) Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab 93:3870–3877. https://doi.org/10.1210/jc.2008-0021 CrossRefPubMedPubMedCentral

Traish AM, Miner MM, Morgentaler A, Zitzmann M (2011) Testosterone deficiency. Am J Med 124:578–587. https://doi.org/10.1016/j.amjmed.2010.12.027 CrossRefPubMed

Li Y, Zhang M, Liu X, Cui W, Rampersad S, Li F, Lin Z, Yang P, Li H, Sheng C, Cheng X, Qu S (2017) Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. Andrology 5:739–743. https://doi.org/10.1111/andr.12360 CrossRefPubMed

Corona G, Sforza A, Maggi M (2017) Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health 35:65–76. https://doi.org/10.5534/wjmh.2017.35.2.65 CrossRefPubMedPubMedCentral

Ng Tang Fui M, Hoermann R, Cheung AS, Gianatti EJ, Zajac JD, Grossmann M (2013) Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status. Andrology 1:906–912. https://doi.org/10.1111/j.2047-2927.2013.00124.x CrossRefPubMed

Rezvani MR, Saadatjou SA, Sorouri S, Hassanpour Fard M (2012) Comparison of serum free testosterone, luteinizing hormone and follicle stimulating hormone levels in diabetics and non-diabetics men- a case-control study. J Res Health Sci 12:98–100PubMed

Rovira-Llopis S, Banuls C, de Maranon AM, Diaz-Morales N, Jover A, Garzon S, Rocha M, Victor VM, Hernandez-Mijares A (2017) Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Radic Biol Med 108:155–162. https://doi.org/10.1016/j.freeradbiomed.2017.03.029 CrossRefPubMed

10.

Atlantis E, Fahey P, Martin S, O’Loughlin P, Taylor AW, Adams RJ, Shi Z, Wittert G (2016) Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocr Disord 16:26. https://doi.org/10.1186/s12902-016-0109-7 CrossRefPubMedPubMedCentral

11.

Xia JW, Tan SJ, Zhang XL, Jun T, Sun XK, Ling W (2015) Correlation of serum testosterone with insulin resistance in elderly male type 2 diabetes mellitus patients with osteoporosis. J Diabetes Investig 6:548–552. https://doi.org/10.1111/jdi.12291 CrossRefPubMedPubMedCentral

12.

Daka B, Langer RD, Larsson CA, Rosen T, Jansson PA, Rastam L, Lindblad U (2015) Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord 15:35. https://doi.org/10.1186/s12902-015-0034-1 CrossRefPubMedPubMedCentral

13.

Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M (2011) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34:528–540. https://doi.org/10.1111/j.1365-2605.2010.01117.x CrossRefPubMed

14.

Sheffield-Moore M (2000) Androgens and the control of skeletal muscle protein synthesis. Ann Med 32:181–186CrossRefPubMed

15.

Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M (2017) Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol 72:1000–1011. https://doi.org/10.1016/j.eururo.2017.03.032 CrossRefPubMed

16.

Nian Y, Ding M, Hu S, He H, Cheng S, Yi L, Li Y, Wang Y (2017) Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials. Andrologia. https://doi.org/10.1111/and.12630 PubMedCrossRef

17.

Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM (2006) Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91:2011–2016. https://doi.org/10.1210/jc.2006-0036 CrossRefPubMed

18.

Li HJ (2014) More attention should be paid to the treatment of male infertility with drugs–testosterone: to use it or not? Asian J Androl 16:270–273. https://doi.org/10.4103/1008-682x.122343 CrossRefPubMedPubMedCentral

19.

Boyanov MA, Boneva Z, Christov VG (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6:1–7CrossRefPubMed

20.

Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, Green K, Makdissi A, Hejna J, Chaudhuri A, Punyanitya M, Dandona P (2016) Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 39:82–91. https://doi.org/10.2337/dc15-1518 CrossRefPubMed

21.

Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, Grossmann M (2014) Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 37:2098–2107. https://doi.org/10.2337/dc13-2845 CrossRefPubMed

22.

Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M (2014) Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 99:3821–3828. https://doi.org/10.1210/jc.2014-1872 CrossRefPubMed

23.

Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, Shah NS (2010) Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 16:570–576. https://doi.org/10.4158/ep09355 CrossRefPubMed

24.

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P (2013) Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 10:1612–1627. https://doi.org/10.1111/jsm.12146 CrossRefPubMed

25.

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P (2014) Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 11:840–856. https://doi.org/10.1111/jsm.12404 CrossRefPubMed

26.

Heufelder AE, Saad F, Bunck MC, Gooren L (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726–733. https://doi.org/10.2164/jandrol.108.007005 CrossRefPubMed

27.

Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–837. https://doi.org/10.2337/dc10-1233 CrossRefPubMedPubMedCentral

28.

Kapoor D, Goodwin E, Channer KS, Jones TH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899–906. https://doi.org/10.1530/eje.1.02166 CrossRefPubMed

29.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):w264CrossRef

30.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869. https://doi.org/10.1136/bmj.c869 CrossRefPubMedPubMedCentral

31.

Pogue JM, Yusuf S (1997) Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 18:580–593 (discussion 661–586) CrossRefPubMed

32.

Pogue J, Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351:47–52. https://doi.org/10.1016/s0140-6736(97)08461-4 CrossRefPubMed

33.

Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286. https://doi.org/10.1093/ije/dyn179 CrossRefPubMed

34.

Zhang J, Xiao L, Qin Z, Xu A, Zhao K, Liang C, Miao C, Zhu J, Chen W, Hua Y, Liu Y, Zhang C, Yu Y, Su S, Wang Z (2016) Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis. Oncotarget 7:67101–67110. https://doi.org/10.18632/oncotarget.11937 PubMedPubMedCentralCrossRef

35.

Li X, Shen M, Cai H, Liu K, Liu Y, Huang Z, Liang C, Deng X, Ye J, Zou Q, Li J (2016) Association between manganese superoxide dismutase (MnSOD) polymorphism and prostate cancer susceptibility: a meta-analysis. Int J Biol Markers 31:e422–e430. https://doi.org/10.5301/jbm.5000188 CrossRefPubMed

36.

Chen P, Li X, Sang L, Huang J (2017) Perioperative intravenous glucocorticoids can decrease postoperative nausea and vomiting and pain in total joint arthroplasty: a meta-analysis and trial sequence analysis. Medicine 96:e6382. https://doi.org/10.1097/md.0000000000006382 CrossRefPubMedPubMedCentral

37.

Yang L, Wang G, Du Y, Ji B, Zheng Z (2014) Remote ischemic preconditioning reduces cardiac troponin I release in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 28:682–689. https://doi.org/10.1053/j.jvca.2013.05.035 CrossRefPubMed

38.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

39.

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114. https://doi.org/10.1016/j.cct.2006.04.004 CrossRefPubMed

40.

Marin P, Krotkiewski M, Bjorntorp P (1992) Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1:329–336PubMed

41.

Tuck SP, Francis RM (2009) Testosterone, bone and osteoporosis. Front Horm Res 37:123–132. https://doi.org/10.1159/000176049 CrossRefPubMed

42.

Brinkmann AO (2011) Molecular mechanisms of androgen action–a historical perspective. Methods Mol Biol 776:3–24. https://doi.org/10.1007/978-1-61779-243-4_1 CrossRefPubMed

43.

Kim KS, Kang SH, Kim MJ, Kim SK, Kim YL, Park WK, Park SW, Cho YW (2014) Low serum testosterone concentrations in hospitalized men with poorly controlled type 2 diabetes. Endocrinol Metab 29:574–578. https://doi.org/10.3803/EnM.2014.29.4.574 CrossRef

44.

Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8:272–283. https://doi.org/10.1111/j.1743-6109.2010.01991.x CrossRefPubMed

45.

Grossmann M, Hoermann R, Wittert G, Yeap BB (2015) Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol 83:344–351. https://doi.org/10.1111/cen.12664 CrossRef

46.

Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol 73:602–612. https://doi.org/10.1111/j.1365-2265.2010.03845.x CrossRef

47.

Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G (2010) Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 7:3495–3503. https://doi.org/10.1111/j.1743-6109.2010.01931.x CrossRefPubMed

48.

Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ (2014) Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 16:146–152. https://doi.org/10.4103/1008-682x.122346 CrossRefPubMed

Titel: Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review
verfasst von: Jianzhong Zhang
Bin Yang
Wenhui Xiao
Xiao Li
Hongjun Li
Publikationsdatum: 06.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 8/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2256-0

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy

Systematic reviews and meta-analysis in stone disease: is this what we need to get stronger evidence?

Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis

Should we rely on Doppler ultrasound for evaluation of testicular solid lesions?

Delays in radical prostatectomy for prostate cancer and survival outcomes

Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie